Profile data is unavailable for this security.
About the company
Guobang Pharma Ltd is a China-based company mainly engaged in the research and development, production, and sales of related products in the field of medicine and animal health products. The Company's pharmaceutical business includes raw materials, key pharmaceutical intermediates and preparations, and its main products include azithromycin, clarithromycin, and roxithromycin cephalosporin series products. The animal health products business includes animal protection raw materials, animal protection additives and preparations. The main products of veterinary antibiotics include florfenicol, enrofloxacin series, etc., and insecticides include diclazuril and cypronamine, and reparation products include premixes, powders, granules, etc.
- Revenue in CNY (TTM)5.28bn
- Net income in CNY616.22m
- Incorporated1996
- Employees4.23k
- LocationGuobang Pharma Ltd#60 Xingmei RoadMeizhu Town, Xincang CountySHAOXING 312500ChinaCHN
- Phone+86 57 181396120
- Fax+86 57 181396129
- Websitehttp://www.gbgcn.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| China Animal Husbandry Industry Co., Ltd | 5.47bn | 339.08m | 9.85bn | 4.33k | 29.06 | 1.76 | -- | 1.80 | 0.3321 | 0.3321 | 5.36 | 5.48 | 0.6331 | 4.13 | 4.89 | 1,264,384.00 | 3.33 | 6.23 | 4.71 | 9.01 | 18.95 | 24.29 | 5.26 | 8.69 | 1.86 | -- | 0.2017 | 31.20 | -8.24 | 4.04 | -26.73 | -0.6127 | 24.20 | -3.77 |
| Zhejiang Hisun Pharmaceutical Co., Ltd. | 10.04bn | -76.94m | 10.07bn | 8.06k | -- | 1.22 | -- | 1.00 | -0.0823 | -0.0823 | 8.45 | 6.86 | 0.5535 | 3.32 | 4.53 | 1,244,871.00 | -0.5084 | 1.95 | -0.8569 | 3.77 | 38.35 | 40.58 | -0.9187 | 3.43 | 0.6303 | -- | 0.4158 | 26.07 | -13.82 | 0.3618 | -119.05 | -- | -31.58 | -- |
| Shanghai Runda Medical Technology Co Ltd | 9.04bn | 214.86m | 10.10bn | 3.32k | 45.34 | 2.34 | -- | 1.12 | 0.3719 | 0.3719 | 15.65 | 7.22 | 0.6219 | 4.66 | 1.56 | 2,727,524.00 | 2.55 | 4.78 | 7.04 | 12.86 | 26.02 | 27.13 | 4.10 | 6.36 | 1.06 | 7.84 | 0.5568 | 12.43 | -12.84 | 8.93 | -34.58 | 0.8514 | 3.88 | 1.03 |
| Zhejiang Medicine Co., Ltd. | 8.04bn | 425.74m | 10.26bn | 6.23k | 23.78 | 1.05 | -- | 1.28 | 0.447 | 0.447 | 8.41 | 10.13 | 0.6329 | 2.91 | 5.57 | 1,290,409.00 | 2.14 | 4.32 | 2.75 | 5.68 | 31.16 | 36.57 | 3.39 | 6.28 | 1.62 | 5.95 | 0.0819 | 58.72 | -3.96 | 2.59 | -20.37 | 3.34 | 12.65 | 0.00 |
| Guobang Pharma Ltd | 5.28bn | 616.22m | 10.44bn | 4.23k | 16.95 | 1.37 | -- | 1.98 | 1.10 | 1.10 | 9.44 | 13.61 | 0.5231 | 2.78 | 8.16 | 1,247,457.00 | 6.08 | 10.36 | 7.86 | 14.24 | 22.91 | 27.49 | 11.63 | 15.01 | 1.82 | -- | 0.2047 | 18.24 | -6.49 | 10.28 | -33.49 | 23.77 | 35.60 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Invesco Great Wall Fund Management Co. Ltd. (Invt Mgmt)as of 30 Jun 2023 | 7.85m | 2.60% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2023 | 3.50m | 1.16% |
| Da Cheng Fund Management Co., Ltd.as of 30 Jun 2023 | 1.30m | 0.43% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 905.78k | 0.30% |
| Wanjia Asset Management Co., Ltd.as of 30 Jun 2023 | 853.97k | 0.28% |
| Tian Hong Asset Management Co., Ltd.as of 30 Jun 2023 | 720.30k | 0.24% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2023 | 580.69k | 0.19% |
| China Asset Management Co., Ltd.as of 30 Jun 2023 | 413.40k | 0.14% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2023 | 323.20k | 0.11% |
| China Merchants Fund Management Co., Ltd.as of 30 Jun 2023 | 237.20k | 0.08% |
